You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NK-1 antagonist

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gynecologic Cancer Trial in Ann Arbor (Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA))

Recruiting
  • Gynecologic Cancer
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Jan 6, 2022

Cocaine Dependence, Alcohol Dependence Trial in Philadelphia (Placebo session 1, Aprepitant session 2, Placebo session 1,

Completed
Has Results
  • Cocaine Dependence
  • Alcohol Dependence
  • Placebo session 1, Aprepitant session 2
  • Placebo session 1, Placebo session 2
  • Philadelphia, Pennsylvania
    University of Pennsylvania, Treatment Research Center
Jul 1, 2020

Prurigo Nodularis Trial in Germany (serlopitant, Placebo)

Completed
Has Results
  • Prurigo Nodularis
  • Berlin-Mitte, Germany
  • +14 more
May 18, 2021

Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

Not yet recruiting
  • Myeloma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

Not yet recruiting
  • Synovial Sarcoma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)

Not yet recruiting
  • Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Cytokine-Induced Memory-like Natural Killer Cells
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 22, 2023

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

Breast Cancer, Chemo-induced Nausea and Vomiting Trial in Hanzhou (Aprepitant, Palonosetron, Fosaprepitant)

Not yet recruiting
  • Breast Cancer
  • Chemotherapy-induced Nausea and Vomiting
  • Hanzhou, Zhejiang, China
    the Second Affiliated Hospital of Zhejiang Univercity School of
Apr 23, 2023

Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)

Recruiting
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Human BCMA targeted CAR-NK cells injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 13, 2023

Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck Trial (WU-NK-101 - Dose Escalation, Cetuximab - Dose

Not yet recruiting
  • Colorectal Cancer Metastatic
  • Squamous Cell Carcinoma of Head and Neck
  • WU-NK-101 - Dose Escalation
  • +3 more
  • (no location specified)
Dec 30, 2022

Acute Myeloid Leukemia, MDS, Myeloproliferative Tumor Trial in Boston (CIML NK, Fludarabine, Cyclophosphamide)

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CIML NK
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 6, 2023

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus Trial in Lahore (NK-1R antagonist)

Unknown status
  • Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus
  • NK-1R antagonist
  • Lahore, Punjab, Pakistan
    Bahria International Hospital
Jul 10, 2020

PD-1 Antibody, DC-Cell, NK-Cell Trial (Pembrolizumab, Nivolumab, Sintilimab)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • (no location specified)
Jul 14, 2022

Acute Myeloid Leukemia Trial (WU-NK-101)

Not yet recruiting
  • Acute Myeloid Leukemia
  • WU-NK-101
  • (no location specified)
Jul 20, 2022

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

Epidermolysis Bullosa Trial in Redwood City (Serlopitant Tablet, Placebo Oral Tablet)

Completed
Has Results
  • Epidermolysis Bullosa
  • Serlopitant Tablet
  • Placebo Oral Tablet
  • Redwood City, California
    Stanford University
Nov 30, 2022

Arterial Stiffness, Hypertension, Cardiovascular Diseases Trial in Prague (Cardiovascular fitness)

Active, not recruiting
  • Arterial Stiffness
  • +2 more
  • Cardiovascular fitness
  • Prague, Czechia
  • +1 more
Sep 14, 2023

Acute Myeloid Leukemia Trial (NK cells, Talazoparib 1 MG [Talzenna])

Not yet recruiting
  • Acute Myeloid Leukemia
  • NK cells
  • Talazoparib 1 MG [Talzenna]
  • (no location specified)
Jan 9, 2023

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023